Bibliography and glossary of terms - CME Outfitters

A live CME symposium to be held in conjunction with OBESITY2010
Obesity, Diabetes, & Diet:
COMBINING EVIDENCE FOR ALL THREE
INTO IMPROVED PATIENT CARE
Glossary of Terms
and Bibliography

Obesity, Diabetes, & Diet:
COMBINING EVIDENCE FOR ALL THREE INTO IMPROVED PATIENT CARE
GLOSSARY OF TERMS
5-HT2C Serotonin receptor 2C
A1C Glycosylated hemoglobin
ACEI Angiotensin-converting enzyme inhibitors
AHRQ Agency for Healthcare Research and Quality
BID Twice daily (dosage)
BMI Body mass index
BOCF Baseline observation carried forward
BP Blood pressure
BUP Sustained-release bupropion
CCM Chronic care model
CI Confidence interval
CNS Central nervous system
CV Cardiovascular
CVD Cardiovascular disease
D/C Discontinue
DM Diabetes mellitus
DMII Diabetes mellitus type II
DPP-4 Dipeptidyl peptidase-4
EMR Electronic medical record
ER Extended release
FPG Fasting plasma glucose
GI Gastrointestinal
GLP-1 Glucagon-like peptide-1
HB Hemoglobin
HbA1c Glycated hemoglobin
HCT Hydrochlorothiazide
HDL High-density lipoprotein
HEDIS Healthcare Effectiveness Data and Information Set
ICIC Improving Chronic Illness Care
ICV Intracerebroventricular
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
ILI Intensive lifestyle intervention
IMI Intensive medical intervention
ITT Intention-to-treat
1

Obesity, Diabetes, & Diet:
COMBINING EVIDENCE FOR ALL THREE INTO IMPROVED PATIENT CARE
GLOSSARY OF TERMS, CONTINUED
LDL Low-density lipoprotein
LOCF Last observation carried forward
LOSS Louisiana Obese Subjects Study
LS Least-squared
MD Medical doctor
MET Metformin
MMOL Millimole
MR Meal replacement
NAL Naltrexone
NAMCS National Ambulatory Medical Care Survey
NMOL Nanomole
P Placebo, aka PBO
PA Physical activity
PCP Primary care physician
PLG Polylactide-co-glycolide
PMOL Picomole
PPG Postprandial glucose
PPIP Put Prevention Into Practice
QD Once daily (dosage), aka qd
QPM Every afternoon (dosage)
QW Once weekly (dosage)
RD Registered dietician
RYGB Roux-en-Y gastric bypass
SC Subcutaneously
SE Standard error
SU Sulfonylurea
T2DM Type 2 diabetes mellitus
TC Total cholesterol
TG Triglycerides
TZD Thiazolidinedione
UA Urinalysis
UCC Usual care condition
2

Obesity, Diabetes, & Diet:
COMBINING EVIDENCE FOR ALL THREE INTO IMPROVED PATIENT CARE
BIBLIOGRAPHY
Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by
the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.
Diabetes Care 2005;28:1936-1940.
Ashley JM, St Jeor ST, Schrage JP, et al. Weight control in the physician’s office. Arch Intern Med 2001;161:1599-
1604.
Bardia A, Holtan SG, Slezak JM, Thompson WG. Diagnosis of obesity by primary care physicians and impact on
obesity management. Mayo Clin Proc 2007;82:927-932.
Bravata DM, Smith-Spangler C, Sundaram V, et al. Using pedometers to increase physical activity and improve
health: a systematic review. JAMA 2007;298:2296-2304.
Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function,
compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.
Diabetes Care 2009;32:762-768.
Chen E, Bodenheimer, T. Applying the Chronic Care Model to the management of obesity. Obesity Management
2008;4:227-231.
DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L. Effects of exenatide versus
sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a
randomized, cross-over study. Curr Med Res Opin 2008;24:2943-2952.
Drucker DJ, Buse JB, Taylor K, et al. Exenatide once weekly versus twice daily for the treatment of type 2
diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-1250.
Drucker DJ. Glucagon-like peptides. Diabetes 1998;47:159-169.
Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response
to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005;90:5991-5997.
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in
humans. J Clin Invest 1998;101:515-520.
Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol
2006;31:133-147.
Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3
Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-481.
Garber AJ. Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed
care setting. Am J Manag Care 2010;16(7 Suppl):S187-S194.
Gautier JF, Fetita S, Sobngwi E, Salaun-Martin C. Biological actions of the incretins GIP and GLP-1 and
therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 2005;31:233-242.
General OotS. The Surgeon General’s Vision for a Healthy and Fit Nation 2010. In: (HHS) USDoHaHS, ed.;
2010:1-21.
Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the
treatment of obesity. Obesity (Silver Spring) 2009;17:30-39.
Gutzwiller JP, Drewe J, Goke B, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in
patients with diabetes mellitus type 2. Am J Physiol 1999;276(5 Pt 2):R1541-R1544.
Heller J. Catch-22. New York, NY: Simon & Schuster; 1961.
3

Obesity, Diabetes, & Diet:
COMBINING EVIDENCE FOR ALL THREE INTO IMPROVED PATIENT CARE
BIBLIOGRAPHY, CONTINUED
Initiative NOE. The Practical Guide. Identification, Evaluation, and Treatment of Overweight and Obesity in
Adults. In; 2001:1-94.
Jin W, Patti ME. Genetic determinants and molecular pathways in the pathogenesis of Type 2 diabetes. Clin Sci
(Lond) 2009;116:99-111.
Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential,
patient selection and clinical use. Am J Med 2009;122(6 Suppl):S37-S50.
Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and
hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-
286.
Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial
and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-3089.
Kushner RF. Assessment and Management of Adult Obesity: A Primer for Physicians. Chicago, IL: American
Medical Association; 2003. Available at: athttp://www.ama-assn.org/ama/pub/physician-resources/public-health/
general-resources-health-care-professionals/roadmaps-clinical-practice-series/assessment-management-adultobesity.shtml.
Accessed October 7, 2010.
Kushner RF. Tackling obesity: is primary care up to the challenge? Arch Intern Med 2010;170:121-123.
Larsson H, Holst JJ, Ahren B. Glucagon-like peptide-1 reduces hepatic glucose production indirectly through
insulin and glucagon in humans. Acta Physiol Scand 1997;160:413-422.
McAlpine DD, Wilson AR. Trends in obesity-related counseling in primary care: 1995-2004. Med Care
2007;45:322-329.
Meeran K, O’Shea D, Edwards CM, et al. Repeated intracerebroventricular administration of glucagon-like
peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 1999;140:244-250.
Moretto TJ, Milton DR, Ridge TD, et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in
antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallelgroup
study. Clin Ther 2008;30:1448-1460.
National Committee for Quality Assurance. Healthcare Effectiveness Data and Information Set (HEDIS) 2009.
Vol. 2. Available at: http://www.ncqa.org/Portals/0/HEDISQM/HEDIS2010/2010_Measures.pdf. Released 2010.
Accessed October 7, 2010.
Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all
in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.
Diabetes Care 2009;32:84-90.
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia
by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.
Diabetologia 1993;36:741-744.
Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP. Efficacy and safety of the dipeptidyl peptidase-4
inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately
controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab
2007;9:194-205.
4

Obesity, Diabetes, & Diet:
COMBINING EVIDENCE FOR ALL THREE INTO IMPROVED PATIENT CARE
BIBLIOGRAPHY, CONTINUED
Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Treatment with the human once-weekly
glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and
lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a doubleblind
placebo-controlled study. Diabetes Care 2009;32:1237-1243.
Nauck MA, Vilsboll T, Gallwitz B, Garber A, Madsbad S. Incretin-based therapies: viewpoints on the way to
consensus. Diabetes Care 2009;32 (Suppl 2):S223-S231.
Nauck MA, Wollschlager D, Werner J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36
amide]) in patients with NIDDM. Diabetologia 1996;39:1546-1553.
Pannacciulli N, Le DS, Salbe AD, et al. Postprandial glucagon-like peptide-1 (GLP-1) response is positively
associated with changes in neuronal activity of brain areas implicated in satiety and food intake regulation in
humans. Neuroimage 2007;35:511-517.
Poon T, Nelson P, Shen L, et al. Exenatide improves glycemic control and reduces body weight in subjects with
type 2 diabetes: a dose-ranging study. Diabetes Technol Ther 2005;7:467-477.
Rosenstock J, Ratner RE, Boka G. Dose range effects of the new once daily GLP-1 receptor agonist AVE0010
added to metformin in type 2 diabetes. Presented at the 44th Annual Meeting of the European Association for
the Study of Diabetes; 2008 Sep 7-11; Rome, Italy [Abstract 145].
Ryan DH, Johnson WD, Myers VH, et al. Nonsurgical weight loss for extreme obesity in primary care settings:
results of the Louisiana Obese Subjects Study. Arch Intern Med 2010;170:146-154.
Simkin-Silverman LR, Gleason KA, King WC, et al. Predictors of weight control advice in primary care practices:
patient health and psychosocial characteristics. Prev Med 2005;40:71-82.
Smith SR, Prosser WA, Donahue DJ, Morgan ME, Anderson CM, Shanahan WR. Lorcaserin (APD356), a selective
5-HT(2C) agonist, reduces body weight in obese men and women. Obesity (Silver Spring) 2009;17:494-503.
The Chronic Care Model. The Improving Chronic Care Web site. 2006-2010. Available at: http://www.
improvingchroniccare.org/index.php?p=The_Chronic_Care_Model&s=2. Accessed October 7, 2010.
Turton MD, O’Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding.
Nature 1996;379:69-72.
U.S. Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern
Med 2003;139:930-932.
Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for
obesity. N Engl J Med 2005;353:2111-2120.
Wadden TA, West DS, Neiberg RH, et al. One-year weight losses in the Look AHEAD study: factors associated
with success. Obesity (Silver Spring) 2009;17:713-722.
Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function
in patients with type 2 diabetes: a model-based approach. Diabetes Obes Metab 2008;10:1212-1220.
Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic
control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-
830.
5